COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS
results of clinical trials demonstrate that selective vitamin D receptor agonist paricalcitoldecreases proteinuria in patients with chronic kidney disease (CKD) and hyperparathyreosis.
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2015-03-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/28 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849394350201503744 |
|---|---|
| author | A. V. Rudakova |
| author_facet | A. V. Rudakova |
| author_sort | A. V. Rudakova |
| collection | DOAJ |
| description | results of clinical trials demonstrate that selective vitamin D receptor agonist paricalcitoldecreases proteinuria in patients with chronic kidney disease (CKD) and hyperparathyreosis. |
| format | Article |
| id | doaj-art-a4e3fc198e2b4a03a3ec0fe682b3724b |
| institution | Kabale University |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| publishDate | 2015-03-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj-art-a4e3fc198e2b4a03a3ec0fe682b3724b2025-08-20T03:40:00ZrusIRBIS LLCФармакоэкономика2070-49092070-49332015-03-0152131622COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSISA. V. Rudakova0Sankt-Petersburg Chemical-Pharmaceutical Academyresults of clinical trials demonstrate that selective vitamin D receptor agonist paricalcitoldecreases proteinuria in patients with chronic kidney disease (CKD) and hyperparathyreosis.https://www.pharmacoeconomics.ru/jour/article/view/28secondary hyperparathyreosisnephropathydialysisvitamin d receptor agonistcost effectiveness analysismarkov model |
| spellingShingle | A. V. Rudakova COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS Фармакоэкономика secondary hyperparathyreosis nephropathy dialysis vitamin d receptor agonist cost effectiveness analysis markov model |
| title | COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS |
| title_full | COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS |
| title_fullStr | COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS |
| title_full_unstemmed | COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS |
| title_short | COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS |
| title_sort | cost effectiveness of oral pericalcitol in patients with stage iii iv chronic kidney disease and secondary hyperparathyreosis |
| topic | secondary hyperparathyreosis nephropathy dialysis vitamin d receptor agonist cost effectiveness analysis markov model |
| url | https://www.pharmacoeconomics.ru/jour/article/view/28 |
| work_keys_str_mv | AT avrudakova costeffectivenessoforalpericalcitolinpatientswithstageiiiivchronickidneydiseaseandsecondaryhyperparathyreosis |